- ►dvdres.com [PDF] BD Green, PR Flatt, CJ Bailey - Diabetes & Vascular Disease Research, 2006 - dvr.sagepub.com Abstract I nhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a
strategy for the treatment of type 2 dia- betes. DPP IV rapidly inactivates the
incretin hor- mones glucagon-like peptide-1 (GLP-1) and glucose- dependent ... Cited by 40 - Related articles - BL Direct - All 9 versions
N Irwin, PL McClean, FPM O'Harte, VA Gault, P … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis Ablation of gastric inhibitory polypeptide (GIP)
receptor action is reported to protect against obesity and associated metabolic
abnormalities. The aim of this study was to use prediabetic ob/ob mice to ... Cited by 26 - Related articles - BL Direct - All 5 versions
- ►qub.ac.uk [PDF] BD Green, PR Flatt - Best Practice & Research Clinical Endocrinology & …, 2007 - Elsevier The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are physiological gut peptides with
insulin-releasing and extrapancreatic glucoregulatory actions. Incretin ... Cited by 29 - Related articles - All 17 versions
JJ Meier, B Gallwitz, M Askenas, K Vollmer, … - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 1872–1881 DOI 10.1007/s00125-005-1863-7 ARTICLE
JJ Meier . B. Gallwitz . M. Askenas . K. Vollmer . CF Deacon . JJ Holst . ... Cited by 25 - Related articles - BL Direct - All 3 versions
- ►qub.ac.uk [PDF] BD Green, PR Flatt, CJ Bailey - Expert Opin. Emerging Drugs, 2006 - informahealthcare.com Dipeptidyl peptidase IV (DPP IV) is a ubiquitous, multifunctional, serine
protease enzyme and receptor with roles in the control of endocrine and immune
function, cell metabolism, growth and adhesion. As an enzyme, DPP IV ... Cited by 17 - Related articles - BL Direct - All 6 versions
- ►qub.ac.uk [PDF] BD Green, N Irwin, VA Gault, FP O'Harte, PR … - The British Journal of Diabetes & Vascular Disease, 2005 - dvd.sagepub.com Abstract T he rising prevalence of type 2 diabetes and increasing burden of
diabetic complications requires new approaches to diabetes therapy. An
encouraging new approach for development of future anti-diabetic drugs is ... Cited by 14 - Related articles - All 7 versions
- ►qub.ac.uk [PDF] N Irwin, GC Clarke, BD Green, B Greer, P … - Biochemical pharmacology, 2006 - Elsevier Glucose dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone
with therapeutic potential for type 2 diabetes due to its insulin-releasing and
antihyperglycaemic actions. However, development of GIP-based therapies is ... Cited by 11 - Related articles - All 5 versions
PR Flatt, CJ Bailey, BD Green - Front Biosci, 2008 - qub.ac.uk 1. Abstract 2. Introduction 3. DPP IV and related enzymes 3.1. DPP IV (EC
3.4.14.5) 3.2. Dipeptidyl peptidase II (DPP II) 3.3. Dipeptidyl peptidase 8 (DPP
8) and dipeptidyl peptidase 9 (DPP 9) 3.4. Fibroblast Activation protein ... Cited by 9 - Related articles - View as HTML - All 2 versions
- ►physiology.org JJ Meier, JJ Holst, WE Schmidt, MA Nauck - American Journal of Physiology- Endocrinology And …, 2007 - Am Physiological Soc Changes in hepatic insulin clearance can occur after oral glucose or meal
ingestion. This has been attributed to the secretion and action of gastric
inhibitory polypeptide (GIP) and glucagon-like peptide (GLP)–1. Given the ... Cited by 7 - Related articles - BL Direct - All 5 versions
VA Gault, BD Kerr, N Irwin, PR Flatt - Biochemical Pharmacology, 2008 - Elsevier Glucose-dependent insulinotropic polypeptide has been proposed as a potential
therapeutic for type 2 diabetes, however, efforts to bring forward this drug
have been hindered due to its short circulating half-life. We have adopted ... Cited by 6 - Related articles - All 4 versions
